Lotus Clinical Research, LLC

Lotus Clinical Research, LLC is a global Contract Research Organization (CRO) that specializes in clinical trials focused on central nervous system (CNS) disorders, pain management, obesity, and metabolic diseases. Founded in 2001 in Pasadena, US, Lotus Clinical Research, LLC operates as a CRO providing essential services in clinical trials. The company was acquired by DFW Capital Partners in November 2018, which subsequently facilitated its integration into Continuum Research Group. The CEO, Neil Singla, has a background that supports the company’s objectives in clinical research.

Lotus Clinical Research operates as a global Contract Research Organization (CRO) specializing in clinical trials primarily within the central nervous system (CNS), pain management, obesity, and metabolic diseases. The company's core service offerings include project management, clinical monitoring, medical monitoring, and extensive data management capabilities, facilitated through advanced electronic data capture systems. By leveraging a network of 20 wholly-owned research units and multiple Phase I units, Lotus provides specialized services tailored to both healthy volunteer studies and targeted patient populations. Their clientele comprises pharmaceutical and biotechnology companies seeking to advance their drug development pipelines across international markets, specifically in North America, Europe, and parts of Asia.

Lotus's integrated site network enhances operational efficiency and accelerates study start-up timelines, ultimately producing high-quality data from over 3,400 studies. Lotus Clinical Research generates revenue through a structured transaction model that includes partnerships and collaborations with pharmaceutical and biotechnology firms. These transactions typically involve service agreements that outline specific project deliverables such as clinical trial management, regulatory consulting, and data analysis. The pricing structure for these services is based on the complexity and duration of each clinical trial, with considerations for specialized services like biomarker analysis and patient recruitment strategies.

Specific pricing plans are established during the contract negotiation phase, tailored to the scope of the study and the resources required. Lotus’s ability to provide high-caliber scientific and operational expertise positions them favorably as a preferred CRO partner for organizations looking to navigate the complexities of clinical development in the CNS and metabolic disease sectors. In November 2018, DFW Capital Partners agreed to acquire Lotus Clinical Research, LLC, which was subsequently completed by Continuum Research Group. The company is focusing on expanding its portfolio of clinical trial services, with initiatives aimed at developing new products in the CNS domain.

Furthermore, there are plans to penetrate additional markets in Asia and Europe, targeting completion by the end of 2023. The recent acquisition will enable Lotus to leverage enhanced resources for these expansion efforts.